

Scythian Biosciences Announces Successful Results of Special Meeting of Shareholders

September 17, 2018 08:00 ET | <https://globenewswire.com/news-release/2018/09/17/1571668/0/en/Scythian-Biosciences-Announces-Successful-Results-of-Special-Meeting-of-Sharesholders.html>

Shareholders Approve Strategic Sale of Latin American Assets to Aphria in Exchange for 15,678,310 shares of Aphria (TSX:APH)

Shareholders Approve Name Change to SOL Investments Corp.

Scythian's Issued and Outstanding Shares Expected to be 48,849,218 Post-Closing of the Transaction

TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "**Company**" or "**Scythian**") (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl: SCCYF) is pleased to announce the results of Scythian's special meeting of shareholders on September 14, 2018 ("**Special Meeting**").

At the Special Meeting, shareholders approved the sale of the Company's South American and Caribbean assets to Aphria Inc. (TSX: APH) (the "**Transaction**"), the terms and conditions of which were set out in the Company's management information circular dated August 13, 2018. The Transaction required the approval of a simple majority of the shareholders and, because Aphria is a "related party" to Scythian under applicable securities law, also required the approval of the majority of the minority shareholders in accordance with Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*. The detailed results of the majority of the minority vote were as follows:

Special Matter	Total Votes	Votes For	% Votes For	Votes Against
Approval of the Transaction	10,295,949	10,272,914	99.8%	23,035

The closing of the Transaction is expected to occur on or about the end of September, 2018.

Scythian's shareholders also approved a special resolution authorizing the amendment of the Company's articles to change the name of the Corporation from "Scythian Biosciences

Corp.” to “SOL Investments Corp.” (the “**Name Change**”). The Name Change will take effect following the completion of the Transaction.

On September 14, 2018, the Company announced the entering into of a share purchase agreement with MMJ International Investments Inc. (“**MMJ**”) and all of the shareholders of MMJ. MMJ owns ABP S.A., an Argentinean pharmaceutical distribution company. If completed, and after giving effect to the recently completed acquisitions of MMJ Colombia Partners Inc. and Marigold Acquisitions Inc. the number of issued and outstanding common shares of the Company is expected to be 48,849,218.

About Scythian Biosciences Corp.

Scythian is an international cannabis company with a focus on legal U.S. states. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning Scythian as a future frontrunner in the United States’ medical cannabis industry.

CONTACT INFORMATION

Scythian Biosciences Corp.

Rob Reid, CEO

Phone: (212) 729-9208

Email: info@scythianbio.com

For media inquiries, please contact:

David Schull or Nic Johnson

Russo Partners

(858) 717-2310

david.schull@russopartnersllc.com

nic.johnson@russopartnersllc.com